The Quantellect read.As of Nov 19, 2026, 10 active firms cover Nuvation Bio Inc: 9 rate it Buy or better, 1 sit at Neutral, and 0 rate it Sell or worse, a buy consensus. The target range is very wide, $7.00 to $21.00 (about 3.0x), which points to deep disagreement over how to value the company rather than near-term timing. The average target of $13.22 sits 251% above the current $3.77. The rating mix has held broadly steady over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.06 next quarter toward $-0.08 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS10 active firms
Buy
Strong Buy00%
Buy990%
Neutral110%
Sell00%
Strong Sell00%
Based on 10 active firms as of Nov 19, 2026 (365-day activity window).
12-MONTH PRICE TARGET
$13.22
+250.7% upside
Average target across 9 active firms as of Nov 19, 2026 vs $3.77 current
Highest Target$21.00
Average Target$13.22
Lowest Target$7.00
Detailed analyst forecasts for NUVB
Showing 1–11 of 11 named analysts shown · 10 active firms in the rating projection
As of Nov 19, 2026, 9 of 10 active firms rate NUVB a Buy (1 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
NUVB EPS & revenue forecast
EPS · NEXT QUARTER
$-0.06
Range $-0.12 – $0.00 · 4 analysts · -700% YoY
Next period, 4 analysts expect Nuvation Bio Inc to earn $-0.06 a share (range $-0.12 – $0.00), versus $0.01 a year earlier. Full-year consensus is $-0.29, growing to $-0.08 the year after.
REVENUE · NEXT QUARTER
$56.7M
Range $36.6M – $80.0M · 4 analysts · -32% YoY
Revenue is expected to reach $56.7M (range $36.6M – $80.0M), -31.8% year-over-year. Full-year consensus is $203.2M, rising to $250.9M next year.
Top analysts covering Nuvation Bio Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on NUVB.
#1
David Nierengarten
Wedbush · Rank #24
Buy
$11.00+191.8% to target
Overall win rate
48%
+ Follow
#2
Leonid Timashev
RBC Capital · Rank #27
Buy
$20.00+430.5% to target
Overall win rate
52%
+ Follow
#3
Mayank Mamtani
B. Riley Securities · Rank #36
Buy
$14.00+271.4% to target
Overall win rate
49%
+ Follow
#4
Silvan Tuerkcan
JMP Securities · Rank #69
Buy
$10.00+165.3% to target
Overall win rate
51%
+ Follow
#5
RB
Robert Burns
HC Wainwright & Co. · Rank #215
Buy
$21.00+457.0% to target
Overall win rate
42%
+ Follow
NUVB stock forecast FAQ
What is NUVB's average 12-month price target?+
The 9 active firms with a live target average $13.22 for Nuvation Bio Inc over the next 12 months, ranging from a $21.00 high to a $7.00 low, as of Nov 19, 2026.
Is NUVB stock a Buy, Sell or Neutral right now?+
The current consensus is Buy. Of the 10 active firms as of Nov 19, 2026, 9 rate it Buy or Strong Buy, 1 rate it Neutral, and 0 rate it Sell or Strong Sell.
What are the highest and lowest price targets for NUVB?+
The Street-high target is $21.00 (HC Wainwright & Co.), and the Street-low is $7.00 (UBS). The average of all 9 active-firm targets is $13.22.
How many active Wall Street firms cover NUVB?+
10 active firms have a recognized rating on Nuvation Bio Inc as of Nov 19, 2026, and 9 active firms carry a live 12-month price target.
Who is the most accurate analyst covering NUVB?+
Among analysts who currently cover NUVB, David Nierengarten of Wedbush has the strongest overall Quantellect track record (Rank #24). Their current call is Buy with a $11.00 target.
What is Nuvation Bio Inc's projected EPS for next quarter?+
The consensus estimate is $-0.06 per share (range $-0.12 – $0.00) across 4 analysts. Full-year EPS is projected at $-0.29, rising to $-0.08 the following year.
How much revenue is Nuvation Bio Inc expected to report next quarter?+
Consensus revenue is $56.7M (range $36.6M – $80.0M). Full-year revenue is projected at $203.2M, growing to $250.9M next year.
Have analysts been upgrading or downgrading NUVB lately?+
As of Nov 19, 2026, 9 of 10 active firms rate NUVB a Buy (1 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their NUVB calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.